The Year in IPOs

golden phone with IPO stocks purchase app on the screen on wooden table in office.
Prykhodov / Getty Images/iStockphoto

You can often tell the health of the stock market by the number and performance of initial public offerings, or IPOs. As 2022 has seen a bear market in the major averages, it’s not surprising at all that it hasn’t been a great year for the IPO market either. As of Dec. 5, there were 173 IPOs in the U.S. stock market in 2022, a whopping 82.3% decline from the same period in 2021, during which 980 companies had made their public debut.

See: States Whose Economies Are Failing vs. States Whose Economies Are Thriving
Find Out: 5 Things You Must Do When Your Savings Reach $50,000

The performance of most of these IPOs hasn’t been stellar either. Whereas in boom years big IPOs often jump 50% or more on their first day of trading, 2022 saw a very muted market, with many IPOs now trading well below their initial offering prices. Here are some of the most notable IPOs of 2022, including a quick look at how they’ve traded since they went public.

Bausch & Lomb (BLCO)

  • IPO date: May 6, 2022
  • IPO price: $18
  • Price as of Dec. 9, 2022: $15.22

Bausch & Lomb traded up slightly on its first day, to $18.50, but it was priced at a disappointing level, well below its initial range of $21-$24. The stock remains about 15% below its initial offering price. 

Building Wealth

Belite Bio (BLTE)

  • IPO date: April 29, 2022
  • IPO price: $6
  • Price as of Dec. 9, 2022: $31.12

Belite Bio is one of the few bright spots in the 2022 IPO market. After coming public in the mid-single digits, the stock has posted a gain of about 425%, as of Dec. 9. The biotech company’s products are still in the experimental stage, but it does have one eye disease treatment in late-stage clinical testing.

Take Our Poll: Do You Think People Should Invest In Crypto?

Excelerate Energy (EE)

  • IPO date: April 13, 2022
  • IPO price: $24
  • Price as of Dec. 9, 2022: $27.07

Excelerate Energy, a provider of floating liquefied natural gas terminals, went public at the high end of its $21-$24 initial offering range. In a year in which energy stocks boomed, Excelerate Energy has done better than the market as a whole, sitting about 13% above its IPO price, as of Dec. 9.

Modiv (MDV)

  • IPO date: Feb. 11, 2022
  • IPO price: $25
  • Price as of Dec. 9, 2022: $13.36

Modiv is a real estate investment trust that came to market during a time of skyrocketing interest rates, which increases the firm’s cost of capital. As a result, its share price has been nearly cut in half, although it still sports a healthy 8.34% dividend yield.

Building Wealth


  • IPO date: Jan. 13, 2022
  • IPO price: $29.50
  • Price as of Dec. 9, 2022: $31.88

TPG Inc. is one of the last big private equity firms to go public, and it did so in a decidedly choppy market. However, the stock has held up relatively well in a rough year, up a few percentage points over its IPO price.

Amylyx Pharmaceuticals (AMLX)

  • IPO date: Jan. 7, 2022
  • IPO price: $19
  • Price as of Dec. 9, 2022: $35.65

Amylyx Pharmaceuticals has been a market darling in 2022, nearly doubling from its IPO price in January 2022. A big part of the year’s move came thanks to FDA support for its amyotrophic lateral sclerosis treatment, which drove the stock up about 70% in a single day.

Mobileye Global (MBLY)

  • IPO date: Oct. 26, 2022
  • IPO price: $21
  • Price as of Dec. 9, 2022: $33.70

Mobileye Global has rocketed higher in 2022 on the back of analyst upgrades and a huge potential market. The company develops autonomous driving technology and was spun off from chip maker Intel.

More From GOBankingRates

Building Wealth

Share This Article:

facebook sharing button
twitter sharing button
linkedin sharing button
email sharing button
Building Wealth

About the Author

After earning a B.A. in English with a Specialization in Business from UCLA, John Csiszar worked in the financial services industry as a registered representative for 18 years. Along the way, Csiszar earned both Certified Financial Planner and Registered Investment Adviser designations, in addition to being licensed as a life agent, while working for both a major Wall Street wirehouse and for his own investment advisory firm. During his time as an advisor, Csiszar managed over $100 million in client assets while providing individualized investment plans for hundreds of clients.
Learn More


See Today's Best
Banking Offers